HLAVNÍ TÉMA Novinky ve farmakoterapii plicní arteriální hypertenze | 91 / Vnitř Lék. 2026;72(2):86-91 / VNITŘNÍ LÉKAŘSTVÍ www.casopisvnitrnilekarstvi.cz LITERATURA 1. Galiè N, McLaughlin VV, Rubin LJ, et al. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. [Internet]. 2019 [cit. 2026–01–10]. Available from: https://doi.org/10.1183/13993003.02148-2018. 2. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. [Internet]. 2022 [cit. 2026–01–10]. Available from: https://doi.org/10.1183/13993003.00879-2022. 3. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. [Internet]. 2022 [cit. 2026–01–10]. Available from: https://doi.org/10.1001/jama.2022.4402 4. Vonk Noordegraaf A, Westerhof BE, Westerhof N. The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension. J Am Coll Cardiol. [Internet]. 2017 [cit. 2026–01–10]. Available from: https://doi.org/10.1016/j.jacc.2016. 10. 047. 5. Hoeper MM, Huscher D, Ghofrani HA, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. Int J Cardiol. [Internet]. 2013 [cit. 2026–01–10]. Available from: https://doi.org/10.1016/j.ijcard.2012. 10. 026. 6. Jansa P, Ambrož D, Felšőci M, et al. Current treatment options of pulmonary arterial hypertension in the Czech Republic, its limitations and perspectives, update of the therapeutic algorithm for pulmonary arterial hypertension. Expert consensus statement of the Working Group on Pulmonary Circulation of the Czech Society of Cardiology. Cor et Vasa. [Internet]. 2025 [cit. 2026–01–10]. Available from: https://doi.org/10.33678/cor.2025.046. 7. Hoeper MM, Ewert R, Jansa P, et al. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension. Circulation. [Internet]. 2024 [cit. 2026–01–10]. Available from: https://doi.org/10.1161/ circulationaha.123.068107. 8. Grünig E, Jansa P, Fan F, et al. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension. J Am Coll Cardiol. [Internet]. 2024 [cit. 2026–01–10]. Available from: https://doi.org/10.1016/j.jacc.2023. 10. 045. 9. Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. [Internet]. 2024 [cit. 2026–01–10]. Available from: https://doi. org/10.1183/13993003.01325-2024. 10. Farber HW, Miller DP, Poms AD, et al. Five-Year Outcomes of Patients Enrolled in the REVEAL Registry. Chest. [Internet]. 2015 [cit. 2026–01–10]. Available from: https://doi. org/10.1378/chest.15-0300. 11. Hoeper MM, Pausch C, Grünig E, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. [Internet]. 2021 [cit. 2026–01–10]. Available from: https://doi.org/10.1183/13993003.02024-2021. 12. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. [Internet]. 2010 [cit. 2026–01–10]. Available from: https://doi.org/10.1183/09031936.00057010. 13. Boucly A, Beurnier A, Turquier S, et al. Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension. Eur Respir J. [Internet]. 2024 [cit. 2026–01–10]. Available from: https://doi. org/10.1183/13993003.00197-2024. 14. Sommer N, Ghofrani HA, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. [Internet]. 2020 [cit. 2026–01–10]. Available from: https://doi.org/10.1111/bph.15016. 15. Guignabert C, Humbert M. Targeting transforming growth factor-β receptors in pulmonary hypertension. Eur Respir J. [Internet]. 2020 [cit. 2026–01–10]. Available from: https://doi.org/10.1183/13993003.02341-2020. 16. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med. [Internet]. 2021 [cit. 2026–01–10]. Available from: https://doi.org/10.1056/nejmoa2024277. 17. Souza R, Badesch DB, Ghofrani HA, et al. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J. [Internet]. 2023 [cit. 2026– 01–10]. Available from: https://doi.org/10.1183/13993003.01107-2023. 18. Preston IR, Badesch D, Ghofrani H-A, et al. A long-term follow-up study of sotatercept for treatment of pulmonary arterial hypertension: interim results of SOTERIA. Eur Respir J. [Internet]. 2025 [cit. 2026–01–10]. Available from: https://doi.org/10.1183/13993003.01435-2024. 19. Merck. Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis. Merck.com. [Internet]. Merck [cit. 2026–01–10]. Available from: https://www.merck.com/news/merck-announces-pivotal- -phase-3-zenith-trial-evaluating-winrevair-sotatercept-csrk-met-primary-endpoint-at- -interim-analysis/. 20. Humbert M, McLaughlin VV, Badesch DB, et al. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. [Internet]. 2025 [cit. 2026– 01–10]. Available from: https://doi.org/10.1056/nejmoa2415160. 21. Merck. Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis. Merck.com. [Internet]. Merck [cit. 2026–01–10]. Available from: https://www.merck.com/news/merck-announces-decision-to-stop-phase-3-hyperion-trial-evaluating-winrevair-sotatercept-csrk-early-and-move-to-final-analysis/. 22. McLaughlin VV, Hoeper MM, Badesch DB, et al. Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis. N Engl J Med. [Internet]. 2025 [cit. 2026– 01–10]. Available from: https://doi.org/10.1056/nejmoa2508170. 23. McLaughlin VV. Sotatercept in Pulmonary Arterial Hypertension (STELLAR). American College of Cardiology. [Internet]. American College of Cardiology; 2023 [cited 2026 Feb 28]. Available from: https://www.acc.org/latest-in-cardiology/clinical-trials/2023/03/01/23/49/stellar.
RkJQdWJsaXNoZXIy NDA4Mjc=